Payment overview · 2025
General Payments
$2,142.15
40 reported records · 16 companies
Healthcare provider profile · identity verified
Robert A Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · OCALA, FL · NPI 1982635173
Verified facts
What the public records show
CMS Open Payments records show Robert A Williams, MD received $2,142.15 in general payments during 2025 across 40 reported records.
Novo Nordisk Inc accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $361.59 | 16.9% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $245.77 | 11.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.60 | 9.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $189.68 | 8.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $186.83 | 8.7% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $167.53 | 7.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $136.40 | 6.4% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $112.52 | 5.2% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $107.36 | 5.0% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $100.69 | 4.7% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$99.55 | 4.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $90.69 | 4.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.20 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.61 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.09 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.04 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,142.15 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $354.25 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $189.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $178.50 | 2 | 2025 |
Source payment records
|
|||||
| INSPACE Normalized: inspace |
Device | Stryker Corporation | $167.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $131.15 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.08 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $121.69 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $112.52 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $107.36 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $100.69 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $99.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | E.R. Squibb & Sons, L.L.C. | $90.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $80.33 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $80.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.92 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.84 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $10.93 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $5.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 518 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 135 |
| Oxycodone Hcl | Oxycodone Hcl | 426 | 50 |
| Alprazolam | Alprazolam | 380 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 345 | 94 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 306 | 54 |
| Simvastatin | Simvastatin | 272 | 71 |
| Omeprazole | Omeprazole | 261 | 77 |
| Gabapentin | Gabapentin | 246 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 72 |
| Lisinopril | Lisinopril | 233 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 229 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 61 |
| Furosemide | Furosemide | 210 | 71 |
| Losartan Potassium | Losartan Potassium | 188 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 60 |
| Metformin Hcl | Metformin Hcl | 183 | 51 |
| Potassium Chloride | Potassium Chloride | 158 | 52 |
| Prednisone | Prednisone | 158 | 93 |
| Finasteride | Finasteride | 136 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 36 |
| Metformin Hcl Er | Metformin Hcl | 125 | 41 |
| Trazodone Hcl | Trazodone Hcl | 122 | 34 |
| Carvedilol | Carvedilol | 120 | 37 |
| Fenofibrate | Fenofibrate | 119 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 31 |
| Allopurinol | Allopurinol | 103 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 28 |
| Ibuprofen | Ibuprofen | 97 | 38 |
| Atenolol | Atenolol | 92 | 27 |
| Tramadol Hcl | Tramadol Hcl | 92 | 38 |
| Entresto | Sacubitril/Valsartan | 90 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 85 | 54 |
| Meloxicam | Meloxicam | 83 | 25 |
| Sertraline Hcl | Sertraline Hcl | 82 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 21 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 18 |
| Jardiance | Empagliflozin | 78 | 25 |
| Ozempic | Semaglutide | 78 | 17 |
| Pregabalin | Pregabalin | 77 | 28 |
| Alendronate Sodium | Alendronate Sodium | 76 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 20 |
| Valsartan | Valsartan | 71 | 18 |
| Amoxicillin | Amoxicillin | 70 | 57 |
| Clonazepam | Clonazepam | 70 | 15 |
| Lorazepam | Lorazepam | 68 | 13 |
| Fluconazole | Fluconazole | 67 | 27 |
| Benazepril Hcl | Benazepril Hcl | 66 | 21 |
| Famotidine | Famotidine | 66 | 22 |
| Glimepiride | Glimepiride | 64 | 18 |
| Methylprednisolone | Methylprednisolone | 59 | 49 |
| Azithromycin | Azithromycin | 57 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 14 |
| Diazepam | Diazepam | 53 | 11 |
| Methocarbamol | Methocarbamol | 52 | 13 |
| Farxiga | Dapagliflozin Propanediol | 50 | 14 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 21 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Temazepam | Temazepam | 46 | 11 |
| Eliquis | Apixaban | 45 | 15 |
| Methotrexate | Methotrexate Sodium | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 18 |
| Celecoxib | Celecoxib | 41 | 14 |
| Naproxen Sodium | Naproxen Sodium | 38 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 19 |
| Xarelto | Rivaroxaban | 35 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 12 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Folic Acid | Folic Acid | 32 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 21 |
| Spironolactone | Spironolactone | 29 | 14 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Baclofen | Baclofen | 25 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 16 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 11 |
| Nabumetone | Nabumetone | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,142.15 · 40 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, BREZTRI, BRIUMVI, CREON, FARXIGA, INSPACE, JARDIANCE, Kerendia, LINZESS, NURTEC ODT, OFEV, OTEZLA, Ozempic, PRECIVITYAD2, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYEPTI, XCOPRI, ZAVZPRET, ZEPOSIA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error